Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a … Read more
Polaryx Therapeutics, Inc. Common Stock (PLYX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.167x
Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has a cash flow conversion efficiency ratio of -0.167x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-887.00K) by net assets ($5.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Polaryx Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2024)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Polaryx Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Black Sea Property PLC Ordinary Shares
TA:BSP
|
0.446x |
|
Ceylon Tobacco Company PLC
CM:CTCN0000
|
N/A |
|
CJ Bioscience Inc.
KO:311690
|
N/A |
|
GEPA3F
SA:GEPA3F
|
N/A |
|
UTIMES ORD A (SHH) EQSW Exp:
SHG:688638
|
N/A |
|
Edri-El
TA:EDRL
|
0.013x |
|
AMG Acquisition Corp
V:AMG-P
|
-0.002x |
|
XTC Lithium Limited
AU:XTC
|
-0.140x |
Annual Cash Flow Conversion Efficiency for Polaryx Therapeutics, Inc. Common Stock (2023–2024)
The table below shows the annual cash flow conversion efficiency of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.71 Million | $-2.57 Million | -0.546x | -303.07% |
| 2023-12-31 | $1.28 Million | $-173.00K | -0.135x | -- |